Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants

(2021) Nicholas L Syn et al.   LANCET

IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves

(2021) Na Liu et al.   BMC Medical Research Methodology

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings

(2020) Eduardo Castañon et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Enhancing anti-tumour efficacy with immunotherapy combinations

(2020) Funda Meric-Bernstam et al.   LANCET

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

(2019) Puyuan Xing et al.   Journal for ImmunoTherapy of Cancer

Importance of Considering Competing Risks in Time-to-Event Analyses

(2018) Husam Abdel-Qadir et al.  

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?

(2018) Raghav Sundar et al.   Cancer Discovery

Importance of Considering Competing Risks in Time-to-Event Analyses

(2018) Husam Abdel-Qadir et al.   Circulation-Cardiovascular Quality and Outcomes

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

(2018) Xian Shen et al.   BMJ-British Medical Journal

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

(2017) Eirini Pectasides et al.   Cancer Discovery

Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data

(2015) Lesley A. Stewart et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Do Optimal Prognostic Thresholds in Continuous Physiological Variables Really Exist? Analysis of Origin of Apparent Thresholds, with Systematic Review for Peak Oxygen Consumption, Ejection Fraction and BNP

(2014) Alberto Giannoni et al.   PLoS One

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS